1 / 11

Stroke therapy

Stroke therapy. Aspirin MOA : antiplatelet agent (COX inhibitor -> irreversible platelet inactivation) Recurrent stroke prevention, also Rx acute stroke PK : mixed order clearance, 81mg or 325mg qd

ojal
Télécharger la présentation

Stroke therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stroke therapy

  2. Aspirin MOA: antiplatelet agent (COX inhibitor -> irreversible platelet inactivation) Recurrent stroke prevention, also Rx acute stroke PK: mixed order clearance, 81mg or 325mg qd Toxicity: GI (eg gastritis), bleeding, renal (afferent arteriole constriction -> decrease GFR)

  3. Ticlopidine MOA: antiplatelet agent (irreversible inhibition of ADP-induced platelet aggregation) Declining use but may be slightly better than aspirin Toxicity: diarrhea, leukopenia(CBC after 3 months).

  4. Clopidogrel (plavix TM) MOA: antiplatelet agent (irreversible inhibition of ADP-induced platelet aggregation) Slightly better than aspirin for secondary stroke prevention Toxicity: fewer than ticlopidine (no leukopenia), rare TTP

  5. Dipyridamole MOA: antiplatelet agent (PDE inhibitor -> decrease aggregation) Ineffective alone (use with aspirin or warfarin) Aggrenox: sustained release dipyridamole + aspirin to Rx secondary stroke prevention

  6. Abciximab(ReoPro TM) MOA: antiplatelet agent (mAbFab fragment against platelet glycoprotein IIb-IIIa) Rx unstable angina, off-label Rx stroke (under evaluation).

  7. Heparin MOA: anti-coagulant (glycosaminoglycan mixture activating antithrombin III) Clot formation prevention (e.g Rx crescendo TIA) No role in acute stroke Rx (NOT thrombolytic) PK: IV or SQ only Toxicity: hemorrhage (follow w/ PTT), antidote protamine.

  8. Low MW Heparinoids (lovenox TM or fragmin TM) MOA: anti-coagulant (low MW fraction of heparin) PK: fixed dose Blood test: consider factor Xa

  9. Warfarin (coumadin TM) MOA: anti-coagulant (blocks vitamin K dependent clotting factors) Slow onset (use heparin to tie over) PK: oral, high protein bound -> many drug interactions Toxicity: close monitoring (PT or INR), antidote fresh frozen plasma.

  10. tPA (activase TM or alteplaseTM) MOA: thrombolytic (human enzyme cleaves plasminogen into plasmin) Rx stroke w/in 3 hr of onset PK: IV or IA Toxicity: MANY contraindications -> use with caution.

  11. Urokinase MOA: thrombolytic (human enzyme cleaves plasminogen to plasmin). Not in use anymore.

More Related